Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. | Chris ...

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst ...

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $6.12 / share. This is a decrease of 10.64% from the prior estimate of $6.85 dated April 25, 2026.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Earlier this year, Recursion Pharmaceuticals Inc RXRX initiated discussions with the FDA for the design of a registrational ...

It can take about 10 years (plus or minus a few) for a brand-new clinical compound to go from the early stages of discovery to the market, and those are just the ones that make it that far. Many are ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...